

Thierry Soussi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1525443/publications.pdf>

Version: 2024-02-01

192
papers

15,560
citations

14655

66
h-index

17592

121
g-index

228
all docs

228
docs citations

228
times ranked

14942
citing authors

#	ARTICLE	IF	CITATIONS
1	TP53_PROF: a machine learning model to predict impact of missense mutations in <i>TP53</i> . <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	9
2	<i>TP53</i> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
3	Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases. <i>Frontiers in Oncology</i> , 2022, 12, 808886.	2.8	5
4	Evolutionary history of the p53 family DNA-binding domain: insights from an <i>Alvinella pompejana</i> homolog. <i>Cell Death and Disease</i> , 2022, 13, 214.	6.3	10
5	Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. <i>Cancer Research</i> , 2022, 82, 1492-1502.	0.9	13
6	Benign SNPs in the Coding Region of <i>TP53</i> : Finding the Needles in a Haystack of Pathogenic Variants. <i>Cancer Research</i> , 2022, 82, 3420-3431.	0.9	6
7	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. <i>Cell Death and Differentiation</i> , 2021, 28, 1477-1492.	11.2	26
8	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA <i>TP53</i> Mutations—A Perspective from a Real-World Precision Medicine Cohort. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2612-2620.	4.1	10
9	Prevalence, distribution and predictive value of <i>XPO1</i> mutation in a real-life chronic lymphocytic leukaemia cohort. <i>British Journal of Haematology</i> , 2020, 191, e90-e94.	2.5	3
10	Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries. <i>Scientific Reports</i> , 2020, 10, 20368.	3.3	12
11	Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. <i>Cell Reports</i> , 2019, 28, 1370-1384.e5.	6.4	382
12	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019, 28, 132-144.e3.	6.4	72
13	Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. <i>Genome Research</i> , 2019, 29, 1555-1565.	5.5	28
14	Fam83F induces p53 stabilisation and promotes its activity. <i>Cell Death and Differentiation</i> , 2019, 26, 2125-2138.	11.2	16
15	Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α -Ketoglutarate. <i>Cell Reports</i> , 2019, 27, 820-834.e9.	6.4	36
16	Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux. <i>Cell Death and Disease</i> , 2019, 10, 242.	6.3	15
17	High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering. <i>Human Mutation</i> , 2019, 40, 516-524.	2.5	17
18	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. <i>Nature Communications</i> , 2019, 10, 5385.	12.8	53

#	ARTICLE	IF	CITATIONS
19	The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants. <i>Blood</i> , 2019, 134, 3021-3021.	1.4	0
20	Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. <i>Human Mutation</i> , 2018, 39, 925-933.	2.5	21
21	ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation. <i>Leukemia</i> , 2018, 32, 1070-1080.	7.2	149
22	Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018, 103, e143-e146.	3.5	41
23	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations. <i>Haematologica</i> , 2018, 103, e13-e16.	3.5	18
24	TP53 (Tumour protein p53 (Li-Fraumeni syndrome)). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018, , .	0.1	0
25	MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival. <i>Trends in Cancer</i> , 2018, 4, 602-605.	7.4	6
26	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.9	68
27	Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. <i>Human Mutation</i> , 2017, 38, 339-342.	2.5	20
28	TP53 and 53BP1 Reunited. <i>Trends in Cell Biology</i> , 2017, 27, 311-313.	7.9	4
29	TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. <i>International Journal of Cancer</i> , 2016, 139, 1759-1763.	5.1	18
30	Genetic profiling of CLL: a TP53 addict™ perspective. <i>Cell Death and Disease</i> , 2016, 7, e2042-e2042.	6.3	9
31	TP53: an oncogene in disguise. <i>Cell Death and Differentiation</i> , 2015, 22, 1239-1249.	11.2	227
32	The TP53 Gene Network in a Postgenomic Era. <i>Human Mutation</i> , 2014, 35, 641-642.	2.5	13
33	Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment. <i>Human Mutation</i> , 2014, 35, 756-765.	2.5	170
34	Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB paradigm. <i>Human Mutation</i> , 2014, 35, 643-653.	2.5	15
35	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. <i>Human Mutation</i> , 2014, 35, 672-688.	2.5	294
36	Recommendations for Analyzing and Reporting TP53 Gene Variants in the High-Throughput Sequencing Era. <i>Human Mutation</i> , 2014, 35, 766-778.	2.5	29

#	ARTICLE	IF	CITATIONS
37	The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. <i>Nucleic Acids Research</i> , 2013, 41, D962-D969.	14.5	138
38	Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9551-9556.	7.1	75
39	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. <i>Advances in Cancer Research</i> , 2011, 110, 107-139.	5.0	61
40	P53 (protein 53 kDa). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
41	Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 199-208.	7.4	13
42	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010, 95, 1973-1976.	3.5	124
43	MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. <i>Human Mutation</i> , 2010, 31, 1020-1025.	2.5	26
44	The history of p53. <i>EMBO Reports</i> , 2010, 11, 822-826.	4.5	47
45	TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. <i>Leukemia</i> , 2010, 24, 2072-2079.	7.2	134
46	Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. <i>FEBS Journal</i> , 2009, 276, 4142-4155.	4.7	12
47	When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?. <i>Trends in Molecular Medicine</i> , 2009, 15, 1-4.	6.7	2
48	Mutant p53 protein localized in the cytoplasm inhibits autophagy. <i>Cell Cycle</i> , 2008, 7, 3056-3061.	2.6	262
49	Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. <i>Cancer Biology and Therapy</i> , 2008, 7, 699-708.	3.4	91
50	Breast-cancer stromal cells with TP53 mutations. <i>New England Journal of Medicine</i> , 2008, 358, 1635; author reply 1636.	27.0	6
51	Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 944-954.	1.7	26
52	p53 alterations in human cancer: more questions than answers. <i>Oncogene</i> , 2007, 26, 2145-2156.	5.9	210
53	Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm. <i>Cancer Cell</i> , 2007, 12, 303-312.	16.8	316
54	Analysis of p53 Gene Alterations in Cancer: A Critical View. , 2007, , 255-292.		5

#	ARTICLE	IF	CITATIONS
55	Analysis of p53 Gene Alterations in Cancer: A Critical View. , 2007, , 255-292.		0
56	Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nature Reviews Cancer, 2006, 6, 83-90.	28.4	134
57	The UMD TP53 database and website: update and revisions. Human Mutation, 2006, 27, 14-20.	2.5	125
58	MUT-TP53: a versatile matrix for TP53 mutation verification and publication. Human Mutation, 2006, 27, 1151-1154.	2.5	7
59	Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Annals of Oncology, 2006, 17, 842-847.	1.2	92
60	Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection. Clinical Cancer Research, 2006, 12, 62-69.	7.0	67
61	Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Human Mutation, 2005, 25, 6-17.	2.5	127
62	UMD (Universal Mutation Database): 2005 update. Human Mutation, 2005, 26, 184-191.	2.5	101
63	The p53 pathway and human cancer. British Journal of Surgery, 2005, 92, 1331-1332.	0.3	37
64	The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical Oncology, 2005, 23, 7518-7528.	1.6	331
65	p53 mutation heterogeneity in cancer. Biochemical and Biophysical Research Communications, 2005, 331, 834-842.	2.1	232
66	A New Set of Monoclonal Antibodies Directed to Proline-Rich and Central Regions of p53. Hybridoma, 2004, 23, 287-292.	0.4	2
67	Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array. Clinical Cancer Research, 2004, 10, 3479-3489.	7.0	277
68	Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction. Oncogene, 2004, 23, 5543-5550.	5.9	42
69	Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors. Human Mutation, 2004, 24, 63-75.	2.5	20
70	p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer Cell, 2003, 3, 303-305.	16.8	27
71	Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detection and Prevention, 2003, 27, 182-186.	2.1	22
72	ThinPrep®-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis. Cancer, 2003, 99, 223-232.	4.1	35

#	ARTICLE	IF	CITATIONS
73	The UMD-p53 database: New mutations and analysis tools. <i>Human Mutation</i> , 2003, 21, 176-181.	2.5	136
74	Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. <i>Human Mutation</i> , 2003, 21, 192-200.	2.5	94
75	Focus on the p53 gene and cancer: Advances in TP53 mutation research. <i>Human Mutation</i> , 2003, 21, 173-175.	2.5	22
76	Splice mutations in the p53 gene: case report and review of the literature. <i>Human Mutation</i> , 2003, 21, 101-102.	2.5	60
77	Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway. <i>Oncogene</i> , 2003, 22, 5082-5090.	5.9	12
78	Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. <i>Lung Cancer</i> , 2003, 39, 297-301.	2.0	25
79	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 10546-10555.	3.4	36
80	Lack of HIN-1 Methylation Defines Specific Breast Tumor Subtypes Including Medullary Carcinoma of the Breast and BRCA1-Linked Tumors. <i>Cancer Biology and Therapy</i> , 2003, 2, 559-563.	3.4	15
81	Medullary Breast Carcinoma: Prognostic Implications of P53 Expression. <i>International Journal of Biological Markers</i> , 2003, 18, 99-105.	1.8	12
82	Medullary breast carcinoma: Prognostic implications of p53 expression. <i>International Journal of Biological Markers</i> , 2003, 18, 99-105.	1.8	7
83	Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. <i>Gastroenterology</i> , 2002, 123, 492-504.	1.3	126
84	The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. <i>Gene</i> , 2002, 282, 207-214.	2.2	57
85	An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue. <i>Oncogene</i> , 2002, 21, 1909-1921.	5.9	40
86	Monoclonal antibodies raised against Xenopus p53 interact with human p73. <i>Oncogene</i> , 2002, 21, 1304-1308.	5.9	4
87	Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. <i>Lung Cancer</i> , 2001, 31, 17-23.	2.0	17
88	GÃ©nÃ©tique et cancer: aspects fondamentaux et cliniques. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2001, 5, 36s-41s.	1.4	0
89	Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line. <i>Oncogene</i> , 2001, 20, 3766-3775.	5.9	12
90	Detection of p73 antibodies in patients with various types of cancer: immunological characterization. <i>British Journal of Cancer</i> , 2001, 84, 57-63.	6.4	19

#	ARTICLE	IF	CITATIONS
91	A monoclonal antibody against DNA binding helix of p53 protein. <i>Oncogene</i> , 2001, 20, 1398-1401.	5.9	6
92	Assessing TP53 status in human tumours to evaluate clinical outcome. <i>Nature Reviews Cancer</i> , 2001, 1, 233-239.	28.4	587
93	p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series. <i>Journal of Clinical Oncology</i> , 2000, 18, 1465-1473.	1.6	178
94	Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. <i>International Journal of Cancer</i> , 2000, 89, 81-86.	5.1	40
95	p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. <i>Human Mutation</i> , 2000, 15, 105-113.	2.5	231
96	UMD (Universal Mutation Database): A generic software to build and analyze locus-specific databases. <i>Human Mutation</i> , 2000, 15, 86-94.	2.5	184
97	Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. <i>Journal of Pathology</i> , 2000, 192, 52-57.	4.5	61
98	Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interactions with the mdm2 protein. <i>Journal of Immunological Methods</i> , 2000, 244, 17-28.	1.4	12
99	Serum p53 antibodies: predictors of survival in small-cell lung cancer?. <i>British Journal of Cancer</i> , 2000, 83, 1418-1424.	6.4	30
100	The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation. <i>Annals of the New York Academy of Sciences</i> , 2000, 910, 121-139.	3.8	260
101	Cycle cellulaire et apoptose : le gène suppresseur de tumeur p53.. <i>Medecine/Sciences</i> , 2000, 16, 469.	0.2	1
102	Épidémiologie des cancers : de l'approche descriptive à la biologie moléculaire.. <i>Medecine/Sciences</i> , 2000, 16, 1397.	0.2	0
103	p53 Antibodies in the sera of patients with various types of cancer: a review. <i>Cancer Research</i> , 2000, 60, 1777-88.	0.9	429
104	p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma. <i>Journal of the National Cancer Institute</i> , 1999, 91, 641-643.	6.3	71
105	Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. <i>Oncogene</i> , 1999, 18, 4699-4709.	5.9	19
106	Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. <i>Oncogene</i> , 1999, 18, 3553-3563.	5.9	116
107	Functional analyses of a unique p53 germline mutant (y236?) associated with a familial brain tumor syndrome. , 1999, 82, 17-22.		5
108	Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1999, 26, 1672-5.	2.0	13

#	ARTICLE	IF	CITATIONS
109	Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?. Breast Cancer Research and Treatment, 1998, 47, 47-55.	2.5	37
110	Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein. Oncogene, 1998, 16, 883-890.	5.9	17
111	p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. , 1998, 78, 390-391.		45
112	Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. British Journal of Haematology, 1998, 100, 184-186.	2.5	3
113	p53 mutations in BRCA1-associated familial breast cancer. Lancet, The, 1998, 352, 622.	13.7	12
114	APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Research, 1998, 26, 269-270.	14.5	119
115	Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents. Nucleic Acids Research, 1998, 26, 198-199.	14.5	49
116	p53 gene mutation: software and database. Nucleic Acids Research, 1998, 26, 200-204.	14.5	132
117	SQUAMOUS CELL CARCINOMAS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR APLASTIC ANEMIA. Transplantation, 1998, 66, 667-670.	1.0	53
118	The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis. , 1998, , 221-230.		0
119	P53 : un gène touche à tout dans les points de contrôle du cycle cellulaire après les lésions de l'ADN.. Medecine/Sciences, 1998, 14, 973.	0.2	0
120	Mdm2 et p53 : une association mortelle pour mieux préserver l'intégrité de l'ADN.. Medecine/Sciences, 1998, 14, 656.	0.2	0
121	Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clinical Cancer Research, 1998, 4, 1359-66.	7.0	63
122	Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Research, 1997, 25, 151-157.	14.5	301
123	p53 and APC gene mutations: software and databases. Nucleic Acids Research, 1997, 25, 138-138.	14.5	17
124	Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and both the lacI and lacZ gene in transgenic rodents. Nucleic Acids Research, 1997, 25, 136-137.	14.5	26
125	Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.. Gut, 1997, 40, 356-361.	12.1	73
126	Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene, 1997, 14, 1117-1122.	5.9	143

#	ARTICLE	IF	CITATIONS
127	A functional analysis of p53 during early development of xenopus laevis. <i>Oncogene</i> , 1997, 15, 2191-2199.	5.9	27
128	P53 Gene Alterations in Human Tumors: Perspectives for Cancer Control. <i>Recent Results in Cancer Research</i> , 1997, 143, 369-389.	1.8	48
129	La p53 : un ennemi public que l'on peut attaquer de tous les cts. <i>Medecine/Sciences</i> , 1997, 13, 1339.	0.2	0
130	Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. <i>Blood</i> , 1997, 90, 766-75.	1.4	83
131	The role of p53 in normal cells and in cancer development. <i>Pathologie Et Biologie</i> , 1997, 45, 781-4.	2.2	1
132	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1996, 24, 121-124.	14.5	286
133	The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. <i>Trends in Molecular Medicine</i> , 1996, 2, 32-37.	2.6	51
134	ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. <i>FEBS Letters</i> , 1996, 385, 34-38.	2.8	41
135	Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look. <i>Journal of Molecular Biology</i> , 1996, 260, 623-637.	4.2	201
136	Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. <i>Human Mutation</i> , 1996, 7, 202-213.	2.5	34
137	The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. <i>Trends in Immunology</i> , 1996, 17, 354-356.	7.5	96
138	Software and database for the analysis of mutations in the human FBN1 gene. <i>Nucleic Acids Research</i> , 1996, 24, 137-140.	14.5	41
139	p53 gene mutation: software and database. <i>Nucleic Acids Research</i> , 1996, 24, 147-150.	14.5	82
140	Regulation of Mutant p53 Temperature-sensitive DNA Binding. <i>Journal of Biological Chemistry</i> , 1996, 271, 25468-25478.	3.4	94
141	Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1996, 24, 119-120.	14.5	24
142	Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. <i>Nucleic Acids Research</i> , 1996, 24, 141-146.	14.5	422
143	Analysis of p53 Serum Antibodies in Patients With Head and Neck Squamous Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1228-1233.	6.3	87
144	p53 Autoantibodies. , 1996, , 595-599.		0

#	ARTICLE	IF	CITATIONS
145	Nouveaux modèles murins d'activité du gène suppresseur de tumeur p53. <i>Medecine/Sciences</i> , 1996, 12, 215.	0.2	0
146	Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. <i>Anticancer Research</i> , 1996, 16, 2385-8.	1.1	18
147	The p53 tumor suppressor gene. <i>Advances in Genome Biology</i> , 1995, 3, 55-141.	0.3	2
148	Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. <i>European Journal of Immunology</i> , 1995, 25, 1765-1769.	2.9	90
149	p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue. <i>International Journal of Cancer</i> , 1995, 64, 176-181.	5.1	74
150	Serum p53 antibodies as early markers of lung cancer. <i>Nature Medicine</i> , 1995, 1, 701-702.	30.7	293
151	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.. <i>Gut</i> , 1995, 36, 455-458.	12.1	55
152	p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 1342-1346.	7.1	51
153	Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. <i>Lancet, The</i> , 1995, 345, 621-622.	13.7	138
154	p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. <i>Oncogene</i> , 1995, 10, 9-17.	5.9	94
155	<i>Xenopus laevis</i> p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved. <i>Oncogene</i> , 1995, 10, 779-84.	5.9	17
156	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.. <i>EMBO Journal</i> , 1994, 13, 3496-3504.	7.8	193
157	Detection and Sequencing of p53 Gene Mutations in Bronchial Biopsy Samples in Patients With Lung Cancer. <i>Chest</i> , 1994, 106, 1309-1310.	0.8	0
158	Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 119-125.	2.8	74
159	Multifactorial analysis of p53 alteration in human cancer: A review. <i>International Journal of Cancer</i> , 1994, 57, 1-9.	5.1	287
160	Cancer and the heat shock response. <i>European Journal of Cancer</i> , 1994, 30, 1884-1891.	2.8	127
161	Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1994, 307, 375-386.	1.0	92
162	Effects of Electrical Brainstem Stimulation on Tinnitus. <i>Acta Oto-Laryngologica</i> , 1994, 114, 135-140.	0.9	63

#	ARTICLE	IF	CITATIONS
163	Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. <i>British Journal of Cancer</i> , 1994, 69, 809-816.	6.4	141
164	Functional characterization of <i>Xenopus laevis</i> p53: evidence of temperature-sensitive transactivation but not of repression. <i>Journal of Virology</i> , 1994, 68, 7178-7187.	3.4	9
165	Database and software for the analysis of mutations at the human p53 gene. <i>Nucleic Acids Research</i> , 1994, 22, 3549-50.	14.5	25
166	Database of p53 gene somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1994, 22, 3551-5.	14.5	646
167	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. <i>EMBO Journal</i> , 1994, 13, 3496-504.	7.8	91
168	Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. <i>Oncogene</i> , 1994, 9, 3689-94.	5.9	61
169	p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. <i>Modern Pathology</i> , 1994, 7, 853-9.	5.5	26
170	Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. <i>Chest</i> , 1994, 106, 1309-10.	0.8	0
171	Database and software for the analysis of mutations in the human p53 gene. <i>Cancer Research</i> , 1994, 54, 4454-60.	0.9	58
172	3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation. <i>Cancer Research</i> , 1994, 54, 4502-7.	0.9	11
173	Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. <i>Oncogene</i> , 1994, 9, 2071-6.	5.9	50
174	Stabilization and Expression of High Levels of p53 during Early Development in <i>Xenopus laevis</i> . <i>Developmental Biology</i> , 1993, 159, 163-172.	2.0	46
175	Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. <i>Bulletin Du Cancer</i> , 1993, 80, 102-10.	1.6	11
176	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. <i>Cancer Research</i> , 1993, 53, 5872-6.	0.9	141
177	The cDNA cloning and immunological characterization of hamster p53. <i>Gene</i> , 1992, 112, 247-250.	2.2	24
178	Rainbow trout p53: cDNA cloning and biochemical characterization. <i>Gene</i> , 1992, 112, 241-245.	2.2	71
179	Absence of p53 germ-line mutations in bilateral breast cancer patients. <i>Human Genetics</i> , 1992, 89, 250-2.	3.8	28
180	TP53 tumor suppressor gene: A model for investigating human mutagenesis. <i>Genes Chromosomes and Cancer</i> , 1992, 4, 1-15.	2.8	508

#	ARTICLE	IF	CITATIONS
181	The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. <i>Cancer Research</i> , 1992, 52, 6380-4.	0.9	221
182	Structural aspects of the p53 protein in relation to gene evolution. <i>Oncogene</i> , 1990, 5, 945-52.	5.9	469
183	Evolutionary conservation of the biochemical properties of p53: specific interaction of <i>Xenopus laevis</i> p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70. <i>Journal of Virology</i> , 1989, 63, 3894-3901.	3.4	36
184	Translocation of a Store of Maternal Cytoplasmic c-myc Protein into Nuclei during Early Development. <i>Molecular and Cellular Biology</i> , 1989, 9, 5395-5403.	2.3	24
185	Characterization of a bovine acidic FGF cDNA clone and its expression in brain and retina. <i>FEBS Letters</i> , 1988, 242, 41-46.	2.8	35
186	Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. <i>Nucleic Acids Research</i> , 1988, 16, 11384-11384.	14.5	111
187	Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein. <i>Nucleic Acids Research</i> , 1988, 16, 11383-11383.	14.5	39
188	Cloning and characterization of a cDNA from <i>Xenopus laevis</i> coding for a protein homologous to human and murine p53. <i>Oncogene</i> , 1987, 1, 71-8.	5.9	140
189	DNA-binding properties of the major structural protein of simian virus 40. <i>Journal of Virology</i> , 1986, 59, 740-742.	3.4	43
190	Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. <i>Experimental Cell Research</i> , 1985, 160, 83-94.	2.6	92
191	Stimulation of rat liver $\hat{1}$ - and $\hat{2}$ -type DNA polymerases by an homologous DNA-unwinding protein. <i>FEBS Letters</i> , 1977, 79, 160-164.	2.8	30
192	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1